-
Product Insights
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)- Global Clinical Trials Review, 2025" provides an overview of Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) Clinical trials scenario. This report provides top line data relating to the clinical trials on Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). Report includes an overview of trial numbers and their average enrollment in top countries conducted across...
-
Sector Analysis
HER2-Negative Breast Cancer Epidemiology Analysis and Forecast to 2034
Breast cancer is a malignant tumor originating within the breast tissue. The most common type of breast cancer is invasive breast cancer, which originates from the milk ducts and invades the surrounding breast tissue (Cancer Research UK, 2023a). As it progresses, the cancer can metastasize to other parts of the body via the bloodstream and lymphatic system (American Cancer Society, 2022). According to the World Health Organization (WHO), breast cancer was the most common diagnosed cancer in women in 157...
-
Product Insights
Hormone Sensitive Breast Cancer - Drugs In Development, 2024
Empower your strategies with our Hormone Sensitive Breast Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Estrogen and progesterone promote the growth of some breast cancers, which are called hormone-sensitive (or hormone-dependent) breast cancers. Hormone-sensitive breast cancer cells contain proteins called hormone receptors (estrogen receptors, or ERs, and progesterone receptors, or PRs) that become activated when hormones bind to them. The activated receptors cause changes in the expression of specific genes, which can stimulate cell growth....
-
Sector Analysis
HER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
Reasons to buy the ‘HER2-Positive Breast Cancer Epidemiology’ market report: Get an overview of the HER2+ breast cancer risk factors, comorbidities, and global and historical epidemiological trends in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). Get valuable insights into the 10-year epidemiology forecast for Diagnosed incident cases of all invasive breast cancer Diagnosed incident cases of HER2+ breast cancer Five diagnosed prevalent cases of HER2+ breast cancer Understand the diagnosed incident cases...
-
Product Insights
Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
HER2 Negative Breast Cancer Clinical Trial Analysis Report Overview A total of 2,230 HER2- breast cancer clinical trials were conducted as of February 2024. The following are some of the key highlights of the HER2 breast cancer clinical trial report: As of February 2024, North America led the HER2- breast cancer clinical trials landscape with more than 32% of the clinical trials conducted there. In 2024, Pfizer conducted the highest number of HER2- breast cancer clinical trials. The HER2- breast...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.